ImmuPharma (LON:IMM) Stock Price Up 30.8% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s share price traded up 30.8% on Friday . The company traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.43 ($0.04). 7,318,278 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 23,169,156 shares. The stock had previously closed at GBX 2.63 ($0.03).

ImmuPharma Trading Up 27.6 %

The stock’s 50 day moving average price is GBX 1.59 and its two-hundred day moving average price is GBX 1.69. The firm has a market capitalization of £13.95 million, a price-to-earnings ratio of -335.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.